Skip to main content

Table 2 Changes in the lipid profile and clinical characteristics between baseline and post-treatment values

From: Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)

 

Intention to treat analysis N = 437

 

Baseline

Final

Percent change

Triglycerides (mM/l)

3.01 ± 0.7

1.61 ± 0.8

-44 ± 33*

HDL Cholesterol (mM/l)

0.91 ± 0.1

0.98 ± 0.4

10 ± 52*

Non-HDL cholesterol (mM/l)

4.57 ± 0.9

3.61 ± 1.5

-19 ± 36*

Cholesterol (mM/l)

5.5 ± 0.9

4.57 ± 1.8

-14.9 ± 35*

LDL Cholesterol (mM/l)

3.1 ± 0.9

2.8 ± 1.3

-5.4 ± 59*

  1. Mean ± standard deviation are presented. *p < 0.001 To convert to mg/dl multiple by 89 To convert to mg/dl multiple by 38